APA (7th ed.) Citation

JC, Y., M, W., L, D., Y, F., D, L., M, S., . . . PA, J. (2025). Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(29), 3198. https://doi.org/10.1200/JCO-25-00788

Chicago Style (17th ed.) Citation

JC, Yang, et al. "Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 29 (2025): 3198. https://doi.org/10.1200/JCO-25-00788.

MLA (9th ed.) Citation

JC, Yang, et al. "Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 29, 2025, p. 3198, https://doi.org/10.1200/JCO-25-00788.